XM does not provide services to residents of the United States of America.
E
E

Elekta

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Danske Bank resumes Elekta with 'buy' on pricing power, margins

BUZZ-Danske Bank resumes Elekta with 'buy' on pricing power, margins ** Danske Bank reinitiates coverage of radiation therapy equipment maker Elekta EKTAb.ST with "buy," seeing the Swedish company's margin recovery driven by improving pricing environment and a new, more competitive, product portfolio ** Danske says there is a misconception of stickiness of margin depression among investors and sees clear margin drivers resulting in 2025/26E adj.
E

Elekta, Bristol Myers Squibb Partner On Digital Solution For Patients With Melanoma

BRIEF-Elekta, Bristol Myers Squibb Partner On Digital Solution For Patients With Melanoma Dec 19 (Reuters) - Elekta AB (publ) EKTAb.ST : ELEKTA AND BRISTOL MYERS SQUIBB PARTNER ON DIGITAL SOLUTION FOR PATIENTS WITH MELANOMA Source text for Eikon: ID:nMFN37vSHx Further company coverage: [EKTAb.ST] (Gdansk Newsroom)
E

Abb, Danone, Endesa

EUROPE RESEARCH ROUNDUP-Abb, Danone, Endesa Dec 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Abb, Danone, and Endesa, on Monday. HIGHLIGHTS * Abb Ltd ABBN.S : Citigroup raises to buy from neutral * Danone DANO.PA : Jefferies assumes coverage with buy rating * Endesa ELE.MC : Morgan Stanley cuts to underweight from equal-weight * Ten Entertainment Group Plc TEG.L : Berenberg cuts to hold from buy * Unilever ULVR.L : Jefferies a
A
A
B
B
B
B
B
C
D
E
E
E
E
F
H
H
I
L
L
N
O
R
S
S
T
P
A
F
N
R

'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech

BUZZ-'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech ** Jefferies initiates coverage of eleven European medical technology firms, with seven "buy" ratings, seeing a better 2024 after a downbeat market performance over the past two years ** It says hopes for normalized inflation and stabilizing rates make MedTech attractive
C
E
P
S
S
S
A

European shares post best month since Jan as tumbling inflation spurs rate cut bets

UPDATE 2-European shares post best month since Jan as tumbling inflation spurs rate cut bets For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Italy's FTSE MIB hits 15-year high Euro zone inflation tumble pits ECB against markets ASR jumps after final settlement with interest groups STOXX 600 adds 0.5% Updated at 1650 GMT By Ankika Biswas and Bansari Mayur Kamdar Nov 30 (Reuters) - European shares hit a more than two-month high on Thursday
A
E
E
N
E
F
I
S
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.